<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01052987</url>
  </required_header>
  <id_info>
    <org_study_id>A3008GT</org_study_id>
    <nct_id>NCT01052987</nct_id>
  </id_info>
  <brief_title>Study of Tranilast Alone or in Combination With Allopurinol in Subjects With Hyperuricemia</brief_title>
  <official_title>A Randomized, Double-Blind, Crossover, Pharmacodynamic and Pharmacokinetic Drug Interaction Study of Tranilast in Combination With Allopurinol Compared With Tranilast Alone and Allopurinol Alone in Healthy Subjects With Hyperuricemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nuon Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nuon Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, 3-period 3-treatment crossover followed by a 2-period
      2-treatment crossover, phase 2 study in patients with documented hyperuricemia to evaluate
      the effect of tranilast on allopurinol pharmacokinetics (PK) and pharmacodynamics (PD) and to
      evaluate the effect of allopurinol on tranilast PK and PD as measured by reduction in serum
      uric acid levels.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean percent decrease in serum uric acid levels</measure>
    <time_frame>Seven days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analysis of pharmacokinetic parameters (AUC, Cmax) of tranilast, allopurinol and combination</measure>
    <time_frame>Seven days</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Gout</condition>
  <condition>Hyperuricemia</condition>
  <arm_group>
    <arm_group_label>Tranilast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tranilast tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Allopurinol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Allopurinol tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tranilast plus Allopurinol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose Allopurinol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>400 mg Allopurinol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of Tranilast 300 mg and Allopurinol 400 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranilast</intervention_name>
    <description>Tranilast tablets, 300 mg, QD</description>
    <arm_group_label>Tranilast</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allopurinol</intervention_name>
    <description>Allopurinol tablets 300 mg, QD</description>
    <arm_group_label>Allopurinol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination - Tranilast and Allopurinol</intervention_name>
    <description>Tranilast, 300 mg QD; Allopurinol 300 mg QD</description>
    <arm_group_label>Combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>400 mg Allopurinol</intervention_name>
    <description>400 mg Allopurinol administered once daily for 7 days</description>
    <arm_group_label>High dose Allopurinol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High dose combination</intervention_name>
    <description>Combination of Tranilast 300 mg once daily for 7 days plus Allopurinol 400 mg once daily for 7 days</description>
    <arm_group_label>High dose combination</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, aged 21 to 70

          -  Subjects with hyperuricemia who are otherwise healthy

        Exclusion Criteria:

          -  Pregnant or nursing

          -  Known history of gout unless approved by the Investigator or Sponsor

          -  Clinically significant infection at Screening

          -  Known sensitivity to tranilast or allopurinol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Director, Nuon Clinical Trials Group</last_name>
    <role>Study Director</role>
    <affiliation>Nuon Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nuon Investigative Site</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuon Investigative Site</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuon Investigative Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2010</study_first_submitted>
  <study_first_submitted_qc>January 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2010</study_first_posted>
  <last_update_submitted>January 5, 2011</last_update_submitted>
  <last_update_submitted_qc>January 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2011</last_update_posted>
  <responsible_party>
    <name_title>Nuon Therapeutics Clinical Trials Contact</name_title>
    <organization>Nuon Therapeutics</organization>
  </responsible_party>
  <keyword>Gout</keyword>
  <keyword>Hyperuricemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Allopurinol</mesh_term>
    <mesh_term>Tranilast</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

